Neuste News
- Servier and Pfizer announce FDA clearance of IND application for UCART19 in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia
- Servier announces an increase in turnover for 2015-2016
- Vernalis plc and Servier enter into a new drug discovery collaboration strengthening their existing partnership.
- Pieris Pharmaceuticals and Servier Forge Strategic Immuno-oncology Co-development Alliance
- Servier and Vernalis plc announce achievement of 3 milestones in their oncology drug discovery collaboration
- Servier and CTI BioPharma Expand License and Collaboration Agreement to Develop and Commercialize PIXUVRI®
- Biogaran takes over Swipha’s activities in Nigeria to produce generic drugs for the local market
- Dr Claude BERTRAND, General Director of Research and Development at Servier
- Dr Claude Bertrand, General Director of Research and Development at Servier
- SERVIER RESEARCH FELLOWSHIP awarded by the INTERNATIONAL UNION OF PHLEBOLOGY UNION INTERNATIONALE DE PHLEBOLOGIE / 2017-2019 submission
- Servier Research Fellowship awarded by the International Union of Phlebology - Union Internationale de Phlébologie / 2017-2019 submission
- Servier and Neurochlore join forces to treat autism in children
- Extract of the letter sent to European Medicine Agency (EMA) and national European Agencies on 10 February 2017
- Cessation of marketing of Protelos/Osseor: Extract of the letter sent to European Medicine Agency (EMA) and national European Agencies on 10 February 2017
- Servier and miRagen extend collaboration for the research, development and commercialization of microRNA-targeting therapeutics
